CoChat

Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?

Open access
Daniels, Derek, Mietlicki-Baase, Elizabeth G. · 2019 · Diabetes
Cited by 46

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 (GLP-1) is likely best known by many readers of Diabetes because of the role it plays in insulin secretion. Indeed, GLP-1 receptor (GLP-1R) agonists have become important tools for glycemic control in the treatment of type 2 diabetes. In addition to its incretin effects, GLP-1 signaling plays a role in the control of feeding (1) and other motivated behaviors such as fluid intake (2) and drug taking (3,4). Although many of the effects of GLP-1 are known to be mediated at least in part by activation of central GLP-1Rs, the source(s) of endogenous GLP-1 that activate these receptors remain unclear. Complicating this issue is the fact that GLP-1 is produced both peripherally in the ileum, from which it is released into circulation, and centrally in limited regions of the brain that include the nucleus of the solitary tract (NTS) and the olfactory bulb (1,5) (Fig. 1). Figure 1 GLP-1 interactions with the brain. GLP-1–producing cells (yellow circles) are found in areas including the ileum, olfactory bulb, and hindbrain. GLP-1–responsive structures in the brain are far more distributed and include structures behind (blue) and outside of (red) the blood-brain barrier, a subset of which are represented in this schematic. Knowing which source of GLP-1 acts on which of the responsive structures is important in order to understand the …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dbi18-0045

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Daniels, D., & Mietlicki-Baase, E. G.
Venue
Diabetes
Published
2018-12-13
Volume
68
Issue
1
Pages
15-17
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2906464266
Cited by
46
References
9
FWCI
1.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.